CompletedPHASE1, PHASE2NCT04657315
Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
Studying Gliosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CHA University
- Principal Investigator
- Kyunggi Cho, MD,PhDCHA University
- Intervention
- MSC11FCD(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 19-70 years · All sexes
- Timeline
- 2020 – 2022
Study locations (1)
- Bundang CHA Medical Center, Seongnam, Kyunggido, South Korea
Collaborators
Ajou University School of Medicine
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04657315 on ClinicalTrials.govOther trials for Gliosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07134842A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.University College, London
- ENROLLING BY INVITATIONPHASE1NCT06896110Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade GliomaAndrew P. Groves
- RECRUITINGPHASE1NCT06934889Study of ABBV-637 or ABBV-155 With ERAS-801 for People With GlioblastomaMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT05756985Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain TissueBaptist Health South Florida
- RECRUITINGPHASE2NCT05864534Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaNorthwestern University
- RECRUITINGNCT06954636Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational StudySied Kebir
- RECRUITINGPHASE1NCT04991870Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBMM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT05363826Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®Photolitec LLC